NCT06209736View on ClinicalTrials.gov

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Interventions
DRUG

OMS906 study drug

OMS906 study drug dose 5mg/kg IV administration at 4-week internals

Trial Locations (6)

Unknown

RECRUITING

Omeros Investigational Site, Kaunas

RECRUITING

Omeros Investigational Site, Vilnius

RECRUITING

Omeros Investigational Site, Auckland

RECRUITING

Omeros Investigational Site, Lodz

RECRUITING

Omeros Investigational Site, Leicester

RECRUITING

Omeros Investigational Site, Newcastle upon Tyne

Sponsors

Lead Sponsor

Omeros Corporation
All Listed Sponsors
lead

Omeros Corporation

INDUSTRY

NCT06209736 - Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | Biotech Hunter | Biotech Hunter